Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yuki Kitano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6292-8670; OpenAlex author ID A5016191728, A5100784502. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 8 papers

Papers 20

  1. Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1002/ags3.70297↗
  2. High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1002/jhbp.70032↗
  3. A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. Co-author DOI 10.1007/s12328-025-02256-2↗
  4. A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy. Co-author DOI 10.1007/s12328-026-02359-4↗
  5. The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreatectomy. Co-author DOI 10.1016/j.pan.2026.04.008↗
  6. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Co-author DOI 10.1097/mpa.0000000000002641↗
  7. Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.18442↗
  8. A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. First author DOI 10.70352/scrj.cr.26-0273↗
  9. Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm). Co-author DOI 10.1097/mpa.0000000000002430↗
  10. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  11. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  12. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Co-author DOI 10.1097/mpa.0000000000001997↗
  13. Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.09.007↗
  14. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Co-author DOI 10.1007/s00595-019-01866-x↗
  15. Efficacy of Staging Laparoscopy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14037↗
  16. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  17. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  18. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  19. Cystic gastric metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-018-0443-2↗
  20. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Co-author DOI 10.1007/s10147-016-0975-z↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 12 shared papers, 2020–2026 · strength 2.82
  2. Hirohisa Okabe · 13 shared papers, 2016–2026 · strength 2.60
  3. Masaaki Iwatsuki · 8 shared papers, 2026 · strength 2.24
  4. Shigeki Nakagawa · 9 shared papers, 2018–2026 · strength 1.63
  5. Takanobu Yamao · 9 shared papers, 2018–2026 · strength 1.51
  6. Shinsei Yumoto · 5 shared papers, 2026 · strength 1.36
  7. Rumi Itoyama · 6 shared papers, 2020–2026 · strength 1.17
  8. Tatsunori Miyata · 9 shared papers, 2018–2026 · strength 1.14
  9. Toru Takematsu · 4 shared papers, 2025–2026 · strength 1.08
  10. Takashi Matsumoto · 3 shared papers, 2022–2026 · strength 0.72
  11. Kota Arima · 8 shared papers, 2016–2021 · strength 0.62
  12. Katsunori Imai · 7 shared papers, 2016–2022 · strength 0.60
  13. Akira Chikamoto · 7 shared papers, 2016–2022 · strength 0.58
  14. Yuki Adachi · 2 shared papers, 2026 · strength 0.53
  15. Kosuke Mima · 2 shared papers, 2025–2026 · strength 0.52
  16. Yosuke Nakao · 3 shared papers, 2020–2025 · strength 0.43
  17. Daisuke Hashimoto · 5 shared papers, 2016–2020 · strength 0.36
  18. Kensuke Yamamura · 5 shared papers, 2016–2020 · strength 0.36
  19. Takashi Sasaki · 2 shared papers, 2023–2024 · strength 0.33
  20. Tsuyoshi Takeda · 2 shared papers, 2023–2024 · strength 0.33
  21. Yoshihiro Ono · 2 shared papers, 2023–2024 · strength 0.33
  22. Masato Ozaka · 2 shared papers, 2023–2024 · strength 0.33
  23. Atsushi Oba · 2 shared papers, 2023–2024 · strength 0.33
  24. Hiromichi Ito · 2 shared papers, 2023–2024 · strength 0.33
  25. Yu Takahashi · 2 shared papers, 2023–2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.